Induction of a broad spectrum of inflammation-related genes by Coxsackievirus B3 requires Interleukin-1 signaling

Medical Microbiology and Immunology

Volumn 202, Issue 1, 2013, Pages 11-23

  Rehren, Fabienne ^a   Ritter, Barbara ^a   Dittrich Breiholz, Oliver ^a   Henke, Andreas ^b   Lam, Elena ^a   Kati, Semra ^a   Kracht, Michael ^c   Heim, Albert ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Coxsackievirus B3; IL 1 signaling; IL 1ra; Inflammatory gene induction; Myocarditis

Indexed keywords

INTERLEUKIN 1;

ARTICLE; CCL2 GENE; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; CSF2 GENE; CYTOKINE RESPONSE; DNA MICROARRAY; ENZYME IMMUNOASSAY; FIBROBLAST; FLOW CYTOMETRY; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; IL 1BETA GENE; IL 6 GENE; IL 8 GENE; INFLAMMATION; MMP 1 GENE; MMP 15 GENE; MMP 3 GENE; NONHUMAN; PRIORITY JOURNAL; PTGS2 GENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

CELL LINE; ENTEROVIRUS B, HUMAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-1; MICROARRAY ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84873410044     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-012-0245-2     Document Type: Article

References (73)

1. Feldman AM, McNamara D (2000) Myocarditis. N Engl J Med 343(19):1388-1398
2. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, Kucheryavaya AY, Rahmel AO, Hertz MI (2009) Registry of the international society for heart and lung transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 28(10):1007-1022
3. Kawai C (1999) From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99(8):1091-1100
4. Knowlton KU (2008) CVB infection and mechanisms of viral cardiomyopathy. Curr Top Microbiol Immunol 323:315-335
5. Leslie K, Blay R, Haisch C, Lodge A, Weller A, Huber S (1989) Clinical and experimental aspects of viral myocarditis. Clin Microbiol Rev 2(2):191-203
6. Neumann DA, Burek CL, Baughman KL, Rose NR, Herskowitz A (1990) Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol 16(6):839-846
7. Schwimmbeck PL, Bigalke B, Schulze K, Pauschinger M, Kuhl U, Schultheiss HP (2004) The humoral immune response in viral heart disease: characterization and pathophysiological significance of antibodies. Med Microbiol Immunol 193(2-3):115-119
8. Kishimoto C, Thorp KA, Abelmann WH (1990) Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine Coxsackievirus B3 myocarditis. Circulation 82(3):982-989
9. Latham RD, Mulrow JP, Virmani R, Robinowitz M, Moody JM (1989) Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 117(4):876-882
10. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE (1995) A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. N Engl J Med 333(5):269-275
11. Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO III, Alling D et al (1989) A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321(16):1061-1068
12. Chapman NM, Kim KS (2008) Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr Top Microbiol Immunol 323:275-292
13. McManus BM, Chow LH, Wilson JE, Anderson DR, Gulizia JM, Gauntt CJ, Klingel KE, Beisel KW, Kandolf R (1993) Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 68(2):159-169
14. Yuan J, Cheung PK, Zhang H, Chau D, Yanagawa B, Cheung C, Luo H, Wang Y, Suarez A, McManus BM, Yang D (2004) A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts. Lab Invest 84(6):703-714
15. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Gatewood SJ, Njoku DB, Rose NR (2004) Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol 165(6):1883-1894
16. Figulla HR, Stille-Siegener M, Mall G, Heim A, Kreuzer H (1995) Myocardial enterovirus infection with left ventricular dysfunction: a benign disease compared with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 25(5):1170-1175
17. Heim A, Stille-Seigener M, Pring-Akerblom P, Grumbach I, Brehm C, Kreuzer H, Figulla HR (1996) Recombinant Interferons beta and gamma have a higher antiviral activity than interferon-alpha in coxsackievirus B3-infected carrier state cultures of human myocardial fibroblasts. J Interferon Cytokine Res 16(4):283-287
18. Heim A, Weiss S (2004) Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity. Med Microbiol Immunol (Berl) 193(2-3):149-154
19. Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107(22):2793-2798
20. Matsumori A, Tomioka N, Kawai C (1988) Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 115(6):1229-1232
21. Klingel K, Rieger P, Mall G, Selinka HC, Huber M, Kandolf R (1998) Visualization of enteroviral replication in myocardial tissue by ultrastructural in situ hybridization: identification of target cells and cytopathic effects. Lab Invest 78(10):1227-1237
22. Koide H, Kitaura Y, Deguchi H, Ukimura A, Kawamura K, Hirai K (1992) Genomic detection of enteroviruses in the myocardium-studies on animal hearts with coxsackievirus B3 myocarditis and endomyocardial biopsies from patients with myocarditis and dilated cardiomyopathy. Jpn Circ J 56(10):1081-1093
23. Eghbali M, Czaja MJ, Zeydel M, Weiner FR, Zern MA, Seifter S, Blumenfeld OO (1988) Collagen chain mRNAs in isolated heart cells from young and adult rats. J Mol Cell Cardiol 20(3):267-276
24. Heim A, Brehm C, Stille-Siegener M, Muller G, Hake S, Kandolf R, Figulla HR (1995) Cultured human myocardial fibroblasts of pediatric origin: natural human interferon-alpha is more effective than recombinant interferon-alpha 2a in carrier-state coxsackievirus B3 replication. J Mol Cell Cardiol 27(10):2199-2208
25. Kandolf R, Canu A, Hofschneider PH (1985) Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J Mol Cell Cardiol 17(2):167-181
26. Bedard KM, Semler BL (2004) Regulation of picornavirus gene expression. Microbes Infect 6(7):702-713
27. Heim A, Zeuke S, Weiss S, Ruschewski W, Grumbach IM (2000) Transient induction of cytokine production in human myocardial fibroblasts by coxsackievirus B3. Circ Res 86(7):753-759
28. Henke A, Mohr C, Sprenger H, Graebner C, Stelzner A, Nain M, Gemsa D (1992) Coxsackievirus B3-induced production of tumor necrosis factor-alpha, IL-1 beta, and IL-6 in human monocytes. J Immunol 148(7):2270-2277
29. Garmaroudi FS, Marchant D, Si X, Khalili A, Bashashati A, Wong BW, Tabet A, Ng RT, Murphy K, Luo H, Janes KA, McManus BM (2010) Pairwise network mechanisms in the host signaling response to coxsackievirus B3 infection. Proc Natl Acad Sci USA 107(39):17053-17058
30. Shen Y, Xu W, Chu YW, Wang Y, Liu QS, Xiong SD (2004) Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J Virol 78(22):12548-12556
31. Gluck B, Schmidtke M, Merkle I, Stelzner A, Gemsa D (2001) Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J Mol Cell Cardiol 33(9):1615-1626
32. Kishimoto C, Kuroki Y, Hiraoka Y, Ochiai H, Kurokawa M, Sasayama S (1994) Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage. Circulation 89(6):2836-2842
33. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR (1992) Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med 175(4):1123-1129
34. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR (1993) Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J Immunol 151(3):1682-1690
35. Schmidtke M, Selinka HC, Heim A, Jahn B, Tonew M, Kandolf R, Stelzner A, Zell R (2000) Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1. Virology 275(1):77-88
36. Zautner AE, Korner U, Henke A, Badorff C, Schmidtke M (2003) Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J Virol 77(18):10071-10077
37. Zautner AE, Jahn B, Hammerschmidt E, Wutzler P, Schmidtke M (2006) N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J Virol 80(13):6629-6636
38. Harms W, Rothamel T, Miller K, Harste G, Grassmann M, Heim A (2001) Characterization of human myocardial fibroblasts immortalized by HPV16 E6-E7 genes. Exp Cell Res 268(2):252-261
39. Reed L, Muench, HA (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg (27)
40. Dierssen U, Rehren F, Henke-Gendo C, Harste G, Heim A (2008) Rapid routine detection of enterovirus RNA in cerebrospinal fluid by a one-step real-time RT-PCR assay. J Clin Virol 42(1):58-64
41. Dittrich-Breiholz O, Schneider H, Wehmeier L, Resch K, Kracht M (2003) Entwicklung und Evaluierung eines DNA Mikroarrays für entzü ndungsrelevante Gene. Biospketrum 1/03:88-92
42. Kettner-Buhrow D, Dittrich-Breiholz O, Schneider H, Wolter S, Resch K, Kracht M (2006) Small interfering RNAs generated by recombinant dicer induce inflammatory gene expression independent from the TAK1-NFkappaB-MAPK signaling pathways. Biochem Biophys Res Commun 347(3):566-573
43. Wolf K, Schulz C, Riegger GA, Pfeifer M (2002) Tumour necrosis factor-alpha induced CD70 and interleukin-7R mRNA expression in BEAS-2B cells. Eur Respir J 20(2):369-375
44. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, Laurberg S, Sorensen FB, Hagemann R, TF OR (2002) Gene expression in colorectal cancer. Cancer Res 62(15):4352-4363
45. Houliston RA, Keogh RJ, Sugden D, Dudhia J, Carter TD, Wheeler-Jones CP (2002) Protease-activated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. Thromb Haemost 88(2):321-328
46. Elliott SF, Coon CI, Hays E, Stadheim TA, Vincenti MP (2002) Bcl-3 is an interleukin-1-responsive gene in chondrocytes and synovial fibroblasts that activates transcription of the matrix metalloproteinase 1 gene. Arthritis Rheum 46(12):3230-3239
47. Nagaeva O, Jonsson L, Mincheva-Nilsson L (2002) Dominant IL-10 and TGF-beta mRNA expression in gammadeltaT cells of human early pregnancy decidua suggests immunoregulatory potential. Am J Reprod Immunol 48(1):9-17
48. Jung M, Romer A, Keyszer G, Lein M, Kristiansen G, Schnorr D, Loening SA, Jung K (2003) mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue. Prostate 55(2):89-98
49. Zarember KA, Godowski PJ (2002) Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 168(2):554-561
50. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30(9):e36
51. Henke A, Jarasch N, Martin U, Zell R, Wutzler P (2008) Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-gamma. Viral Immunol 21(1):38-48
52. Tonew M, Wagner B, Wagner M, Schmidtke M, Stelzner A (1996) Permissiveness of human embryonal fibroblasts for coxsackieviruses B3. Investigations on virus genetic markers in vitro and localization of virus receptor distribution by immunogold replica technique. Zentralbl Bakteriol 284(2-3):443-456
53. O'Neill LA, Dinarello CA (2000) The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today 21(5):206-209
54. Triantafilou K, Orthopoulos G, Vakakis E, Ahmed MA, Golenbock DT, Lepper PM, Triantafilou M (2005) Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol 7(8):1117-1126
55. Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, Dawood F, Wen WH, Kozieradzki I, Bachmaier K, Straus D, Mak TW, Penninger JM (2000) The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6(4):429-434
56. Luo H, Yanagawa B, Zhang J, Luo Z, Zhang M, Esfandiarei M, Carthy C, Wilson JE, Yang D, McManus BM (2002) Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J Virol 76(7):3365-3373
57. Esfandiarei M, Luo H, Yanagawa B, Suarez A, Dabiri D, Zhang J, McManus BM (2004) Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol 78(8):4289-4298
58. Kishimoto C, Kawamata H, Sakai S, Shinohara H, Ochiai H (2000) Role of MIP-2 in coxsackievirus B3 myocarditis. J Mol Cell Cardiol 32(4):631-638
59. Yuan H, Ito S, Senga T, Hyodo T, Kiyono T, Kikkawa F, Hamaguchi M (2009) Human papillomavirus type 16 oncoprotein E7 suppresses cadherin-mediated cell adhesion via ERK and AP-1 signaling. Int J Oncol 35(2):309-314
60. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ Jr (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 95(6):2979-2984
61. Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, Yu SS, Kim S, Jeon ES (2002) Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105(11):1278-1281
62. Weinstock-Guttman B, Ramanathan M, Zivadinov R (2008) Interferon-beta treatment for relapsing multiple sclerosis. Exp Opin Biol Ther 8(9):1435-1447
63. Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53(8):1622-1627
64. Nuki G, Bresnihan B, Bear MB, McCabe D (2002) Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(11):2838-2846
65. Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH, Padalko E, Neyts J, Schultheiss HP, Van de Werf F, Carmeliet P, Pinto YM (2006) Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114(6):565-573
66. Tanaka T, Kanda T, McManus BM, Kanai H, Akiyama H, Sekiguchi K, Yokoyama T, Kurabayashi M (2001) Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-alpha. J Mol Cell Cardiol 33(9):1627-1635
67. Huber SA, Polgar J, Schultheiss P, Schwimmbeck P (1994) Augmentation of pathogenesis of coxsackievirus B3 infections in mice by exogenous administration of interleukin-1 and interleukin-2. J Virol 68(1):195-206
68. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y (2000) Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191(2):313-320
69. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW (2000) Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 191(2):303-312
70. Westphal E, Rohrbach S, Buerke M, Behr H, Darmer D, Silber RE, Werdan K, Loppnow H (2008) Altered interleukin-1 receptor antagonist and interleukin-18 mRNA expression in myocardial tissues of patients with dilatated cardiomyopathy. Mol Med 14(1-2):55-63
71. Apte RN, Voronov E (2008) Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 222:222-241
72. Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, Lucking AJ, Flather MD, Lees B, Foley CE (2008) Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 9:8
73. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos PN, Kremastinos DT (2008) Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117(20):2662-2669